Literature DB >> 12740383

The Wnt signaling inhibitor dickkopf-1 is required for reentry into the cell cycle of human adult stem cells from bone marrow.

Carl A Gregory1, Harpreet Singh, Anthony S Perry, Darwin J Prockop.   

Abstract

Adult human mesenchymal stem cells from bone marrow stroma (hMSCs) differentiate into numerous mesenchymal tissue lineages and are attractive candidates for cell and gene therapy. When early passage hMSCs are plated or replated at low density, the cultures display a lag phase of 3-5 days, a phase of rapid exponential growth, and then enter a stationary phase without the cultures reaching confluence. We found that as the cultures leave the lag phase, they secrete high levels of dickkopf-1 (Dkk-1), an inhibitor of the canonical Wnt signaling pathway. The addition of recombinant Dkk-1 toward the end of the lag period increased proliferation and decreased the cellular concentration of beta-catenin. The addition of antibodies to Dkk-1 in the early log phase decreased proliferation. Also, expression of Dkk-1 in hMSCs decreased during cell cycle arrest induced by serum starvation. The results indicated that high levels of Dkk-1 allow the cells to reenter the cell cycle by inhibiting the canonical Wnt/beta-catenin signaling pathway. Since antibodies to Dkk-1 also increased the lag phase of an osteosarcoma line that expressed the gene, Dkk-1 may have a similar role in some other cell systems.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12740383     DOI: 10.1074/jbc.M300373200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  94 in total

1.  A transgenic, mesodermal specific, Dkk1 mouse model recapitulates a spectrum of human congenital limb reduction defects.

Authors:  Filemon Dela Cruz; Melissa Terry; Igor Matushansky
Journal:  Differentiation       Date:  2012-03-08       Impact factor: 3.880

Review 2.  One strategy for cell and gene therapy: harnessing the power of adult stem cells to repair tissues.

Authors:  Darwin J Prockop; Carl A Gregory; Jeffery L Spees
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-17       Impact factor: 11.205

Review 3.  Tomorrow's skeleton staff: mesenchymal stem cells and the repair of bone and cartilage.

Authors:  W R Otto; J Rao
Journal:  Cell Prolif       Date:  2004-02       Impact factor: 6.831

Review 4.  Molecular mediators of mesenchymal stem cell biology.

Authors:  Maria P Alfaro; Sarika Saraswati; Pampee P Young
Journal:  Vitam Horm       Date:  2011       Impact factor: 3.421

5.  Sox11 is expressed in early progenitor human multipotent stromal cells and decreases with extensive expansion of the cells.

Authors:  Benjamin L Larson; Joni Ylostalo; Ryang H Lee; Carl Gregory; Darwin J Prockop
Journal:  Tissue Eng Part A       Date:  2010-07-13       Impact factor: 3.845

6.  Aggregation of human mesenchymal stromal cells (MSCs) into 3D spheroids enhances their antiinflammatory properties.

Authors:  Thomas J Bartosh; Joni H Ylöstalo; Arezoo Mohammadipoor; Nikolay Bazhanov; Katie Coble; Kent Claypool; Ryang Hwa Lee; Hosoon Choi; Darwin J Prockop
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-19       Impact factor: 11.205

7.  Association of serum Dkk-1 levels with β-catenin in patients with postmenopausal osteoporosis.

Authors:  Jun Tian; Xiao-Juan Xu; Lin Shen; Yan-Ping Yang; Rui Zhu; Bo Shuai; Xi-Wen Zhu; Cheng-Gang Li; Chen Ma; Lin Lv
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-04-16

Review 8.  Renal repair: role of bone marrow stem cells.

Authors:  Fangming Lin
Journal:  Pediatr Nephrol       Date:  2008-06       Impact factor: 3.714

9.  The roles of Wnt signaling modulators Dickkopf-1 (Dkk1) and Dickkopf-2 (Dkk2) and cell maturation state in osteogenesis on microstructured titanium surfaces.

Authors:  Rene Olivares-Navarrete; Sharon Hyzy; Marco Wieland; Barbara D Boyan; Zvi Schwartz
Journal:  Biomaterials       Date:  2009-12-09       Impact factor: 12.479

Review 10.  Novel immunotherapies.

Authors:  Qing Yi
Journal:  Cancer J       Date:  2009 Nov-Dec       Impact factor: 3.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.